hVIVO plc

Equities

HVO

GB00B6ZM0X53

Healthcare Facilities & Services

Delayed London S.E. Other stock markets			5-day change	1st Jan Change
- ^GBX	-.--%		+18.92%	+41.94%

02-14	Hvivo Completes Secondary Placing	MT
02-14	Hvivo Shareholders Plan Secondary Placing to Sell 14 Million Shares	MT

HVIVO Asian growth strategy bearing fruit with second 2023 contract win

February 09, 2023 at 08:01 am

(via NewsDirect)

hVIVO PLC (AIM:HVO) Director of Business Development for Europe and Asia Egle Pavyde speaks to Proactive's Thomas Warner after announcing the company's second contract win of the year in the Asia-Pacific region. Pavide reveals more details about the contract and says she is delighted with the progress made in exploring new opportunities in what she calls a rapidly growing market.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Latest news about hVIVO plc

Hvivo Completes Secondary Placing	02-14	MT
Hvivo Shareholders Plan Secondary Placing to Sell 14 Million Shares	02-14	MT
Hvivo Wins GBP6 Million Antiviral Testing Contract	01-02	MT
Hvivo Secures GBP17 Million Contract for RSV Antiviral Drug Testing; Stock Surges	12-13	MT
Earnings Flash (HVO.L) HVIVO Reports H1 Revenue GBP27.3M	12/09/23	MT
Earnings Flash (HVO.L) HVIVO Posts H1 EPS GBX0.58	12/09/23	MT
HVIVO Limited Reports Earnings Results for the Half Year Ended June 30, 2023	12/09/23	CI
Lab Services Company Hvivo to Build New London Facility	29/08/23	MT
HVIVO plc Plans for A New Facility to Meet Growing Demand	29/08/23	CI
Hvivo Wins GBP13 Million Contract from Global Pharma Client	25/07/23	MT
HVIVO Surges 10% on GBP7 Million RSV Drug Testing Contract With Asian Pacific Drugmaker	06/02/23	MT
UK's hVIVO Signs GBP2.5 Million Contract for RSV Vaccine Candidate Testing	04/01/23	MT
HVIVO Up 9% With $16 Million Antiviral Testing Contract	10/11/22	MT
HVIVO Announces £10.4 Million Contract with Existing Big Pharma Client	22/08/22	CI
Cocrystal Pharma Engages hVIVO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344	08/08/22	CI
HVIVO Limited Signs £6.2 Million Influenza Human Challenge Study Contract	04/08/22	CI
Hvivo Signs £7.2 Million Contract with an Existing Top 5 Global Pharmaceutical Company to Test Its Orally Administered Antiviral Product	14/06/22	CI
HVIVO Signs GBP 14.7 Million Influenza Contract	01/06/22	CI
HVIVO Signs a £7.3 Million Influenza Human Challenge Study Contract Win	18/05/22	CI
HVIVO Receives New Study with an Existing Big Pharma Client to Act as A Vaccination Site for A Phase II Field Study	05/05/22	CI
HVIVO Signs Substantial Contract with an Existing Top 5 Global Pharmaceutical Client to Manufacture Virus for Use in Human Challenge Studies	04/05/22	CI
HVIVO Wins £5 million RSV Human Challenge Study Contract	25/03/22	CI
HVIVO Announces Positive Results from RSV Human Challenge Study	17/02/22	CI
HVIVO Signs £5 Million Influenza Human Challenge Study Contract with a Biotech Company	21/12/21	CI
Hvivo Limited Signs $13.4 Million Contract with A US-Based Biotechnology Company to Test Its Novel Antiviral Candidate Using the Hvivo Influenza Human Challenge Study Model	10/12/21	CI

Chart hVIVO plc

Duration

Period

More charts

Company Profile

hVIVO Holdings Limited, formerly hVIVO Limited, is a holding company. The Company is engaged in a life sciences business pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, respiratory syncytial virus (RSV), asthma and common cold. It has commercialized approximately four disease models, enrolled over 2,000 subjects and conducted approximately 40 product validation studies for a range of industry, government and academic clients and collaborators. The Company offers services, such as challenge study services, lab services, and target and biomarker discovery. It offers viral challenge studies in healthy volunteers in influenza, human rhinovirus (HRV) and RSV. Its lab services include assay development, transfer and optimization across the immunological, molecular and cell-based assay platforms, including offering options in sample matrix testing and specialty biomarker assays.

Sector

Healthcare Facilities & Services

More about the company

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
HVIVO PLC	+41.94%	18.04M
HCA HEALTHCARE, INC.	+20.64%	83.73B
CVS HEALTH CORPORATION	-28.19%	72.21B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-0.35%	26.2B
FRESENIUS SE & CO. KGAA	+1.39%	17.18B
LABCORP HOLDINGS INC.	-10.31%	17.09B
QUEST DIAGNOSTICS INCORPORATED	+2.19%	15.18B
NATERA, INC.	+78.22%	13.59B
TENET HEALTHCARE CORPORATION	+79.75%	13.11B
PURE HEALTH HOLDING	-22.98%	12.92B

Other Healthcare Facilities & Services